Jefferies analyst Brian Tanquilut walked away from meetings we with Tenet Healthcare management “sensing their excitement and optimism for current volume and labor trends,” as well as the improvements to the business in recent quarters that are translating to better cost management and higher earnings visibility, the analyst tells investors. With hospital volume and acuity remaining strong, the firm remains positive on Tenet and maintains a Buy rating and $95 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on THC:
- Tenet Healthcare price target raised to $81 from $65 at Deutsche Bank
- Tenet Healthcare price target raised to $77 from $64 at Stephens
- Tenet Healthcare price target raised to $84 from $74 at Truist
- Tenet Healthcare price target raised to $85 from $72 at Raymond James
- Tenet Healthcare price target raised to $84 from $73 at RBC Capital